MDMA Assisted Therapy
We support you in the application process to access MDMA Assisted Therapy for treatment-resistant mental health concerns.
MDMA Assisted Therapy is an option that can be explored when other modalities such as antidepressants or talk-therapy don’t work, and has been used as an adjunct to therapy since the 1970’s. While it’s safety and effectiveness are still under investigation, Health Canada allows physicians to request access for unique cases of treatment-resistant mental health concerns, specifically PTSD.
MDMA & its potential benefits
This therapy combines the use of MDMA, a psychoactive compound, with talk therapy to help clients process traumatic experiences and emotions in a safe and supportive environment. During therapy sessions, the effects of MDMA, such as increased empathy, well-being, and openness to self-reflection, create optimal conditions for clients to engage in the processing of difficult or traumatic experiences. Studies have shown that MDMA-Assisted Therapy demonstrates greater therapeutic efficacy than any other therapy or medication for PTSD, with more than two-thirds of clients no longer meeting the criteria for PTSD when measured one year after treatment.
- Enhanced emotional processing: Lowers psychological defenses to better process traumatic memories
- Reduced fear and anxiety: Creates a safe space for confronting trauma by reducing anxiety
- Increased empathy and connection: Boosts feelings of empathy and connection, improving therapeutic relationships
- Improved PTSD symptoms: Offers significant symptom reduction for those struggling with PTSD
- Lasting effects from limited sessions: Produces enduring benefits from a few treatment sessions
- Potential for treating other conditions: Shows promise for treating a range of mental health issues beyond PTSD
Ready to get started?
Applying to access MDMA Assisted Therapy
Clients can apply to access this unique mental health treatment through a specific application process, even though this treatment has not yet received official approval. This application process provides a unique opportunity for individuals dealing with challenging mental health conditions.
Recognizing the complexities and challenges of navigating the application process, ATMA CENA, alongside healthcare professionals, facilitates the entire application process on behalf of the clients. This includes assistance from application submission to the delivery of MDMA Assisted Therapy, simplifying the journey toward accessing this potentially life-changing treatment. Our dedicated effort aims to bring relief and hope to those seeking alternative solutions in their healthcare journey, making innovative therapeutic options more accessible to those in need.
Our MDMA Assisted Therapy program
Health Canada Application Fee
To gain access to MDMA, special approval from Health Canada is required. We can facilitate this application for you.
This application fee is non-refundable.
$500 CAD
First & Second Doses of MDMA
Each dose of MDMA is paired with therapy. This process includes a psychiatric assessment & clinical assessment.
A medicine session takes 6 hours and requires at least 8 hours of additional clinical and therapy support.
$6,390 CAD
Third Dose of MDMA
A third dose may be administered as needed, paired with therapy and assessments.
$2,395 CAD
Schedule a free Information
Call to get started
Learn more about MDMA
- MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study (pharmacytimes.com)
- FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Therapy for PTSD, Agrees on Special Protocol Assessment for Phase 3 Trials – Multidisciplinary Association for Psychedelic Studies – MAPS
- New Study Finds MDMA Effective in Treatment of PTSD | Psychology Today
- What to Know About Guided Psychedelic Therapy in Canada | Best Health (besthealthmag.ca)
Disclaimer
MDMA has not received approval from Health Canada or the Food and Drug Administration for treating any mental health conditions. This page offers information strictly for educational purposes and does not comprehensively cover the current research on psychedelic treatments, including their effectiveness, contraindications, risks, side effects, or other relevant details. For further information, please refer to our Disclaimers in our
Terms of Use.